Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis 22.10.2024 / 12:30 CET/CEST The issuer is solely responsible ...
It’s a go for the two phase III Ensure studies of Immunic Inc.’s lead asset in treating relapsing multiple sclerosis. An unblinded data monitoring committee’s interim futility analysis concluded that ...
But did you know that dairy products can make some drugs less effective? This effect is particularly problematic for certain classes of antibiotics, which are drugs used to treat bacterial infections.